Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Terry D. who wrote (3100)	5/23/1999 1:35:00 PM
From: shero	Read Replies (1) \| Respond to of 3702

Let me distract you with some facts. All this talk of Dr. Sturm made me decide to review some documents from my TCLN "due diligence" file. Actually its like the archives and takes up almost 1/2 a file cabinet drawer. Anyway, as Sergant Joe Friday says, "Just the facts"--drum roll... "In collaboration with Drs. Stephen Sturm and Laura Thompson at the Brotman Medical Center, Culver City, Ca and Dr. Stan Mills at the Oklahoma Medical Center, a new therapeutic trial was initiated to test the clinical effectivness of TNT-1 in the treatment of patients with advanced prostate cancer. Under the sponsorship of the Patients Advocate for Advanced Cancer Treatment (PAACT), a physician's sponsored IND (#4111) was obtained to study the effects of weekly x3 doses of biotinylated TNT-1 (50mg/dose) followed 4 days later by 20 mCi of I-131 labeled streptavidan (2-5 mg/dose)." It goes on and on so I won't. My info was from something made available to me copyrighted in 1993. here is the summary 1) rapid uptake of radiolabeled streptavidin in the bony metasases first seen a 5 hrs. 2) rapid clearance of blood pool seen at 24 hrs. 3) evidence of tumor destruction... 4) decreased bone pain in 3 patients 5) COMPLETE REMISSION (not my words) in one patient with PSA levels returning to near normal. (At the time of that report the patient had been in remission over 2 years) PSA went from 210 to 6.2 by day 240. There you have it. And this study is 8 years old, so why should anyone (except the shareholders) be in a hurry now? Certainly cancer patients can wait! (heavy sarcism).